Your session is about to expire
← Back to Search
Functional magnetic resonance imaging (fMRI) for Epilepsy
N/A
Waitlist Available
Led By Steven A Messina, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
- Patients who have previously undergone anterior thalamic nucleus deep brain stimulation (DBS) for refractory epilepsy.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up results would be available immediately following processing of the imaging data after each scan
Awards & highlights
Study Summary
This trial will help researchers learn more about how DBS works in the ANT to treat conditions like Parkinson's disease.
Eligible Conditions
- Epilepsy
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ results would be available immediately following processing of the imaging data after each scan
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~results would be available immediately following processing of the imaging data after each scan
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Document brain activation networks with ANT stimulation
Side effects data
From 2022 Phase 2 trial • 182 Patients • NCT0296687319%
Gastrointestinal Discomfort
16%
Viral Upper Respiratory Tract Infections (Cold)
10%
Nausea
10%
Injury
9%
Muscle or Joint Pain
5%
Flatulence
4%
Headache/Migraine
3%
Sinusitis
2%
Pneumonia
2%
Anxiety
2%
Constipation
1%
Stroke
1%
Sepsis
1%
Pancreatitis
1%
Bladder Infection
1%
Injury/Accident
100%
80%
60%
40%
20%
0%
Study treatment Arm
N-Acetylcysteine (NAC) Treatment Group
Placebo Group
Trial Design
1Treatment groups
Experimental Treatment
Group I: Anterior Nucleus of the Thalamus (ANT) Deep Brain Stimulation (DBS)Experimental Treatment1 Intervention
Subjects that have undergone DBS placement for treatment of refractory epilepsy will undergo a fMRI scan. During the fMRI, the subject will undergo alternating short periods of their DBS in the "on" and "off" state with high- and low frequency settings to measure the brain activation changes induced by the DBS.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Functional magnetic resonance imaging (fMRI)
2019
Completed Phase 4
~240
Find a Location
Who is running the clinical trial?
Mayo ClinicLead Sponsor
3,183 Previous Clinical Trials
3,759,011 Total Patients Enrolled
22 Trials studying Epilepsy
1,192 Patients Enrolled for Epilepsy
Steven A Messina, MDPrincipal InvestigatorMayo Clinic
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger